Abstract:AIM To evaluate the prognostic factors and tumor stages of the 7(th) edition TNM classification for esophageal cancer. METHODS In total, 1033 patients with esophageal squamous cell carcinoma (ESCC) who underwent surgical resection with or without (neo)adjuvant therapy between January 2003 and June 2012 at the Thoracic Surgery Department II of the Beijing Cancer Hospital, Beijing, China were included in this study. The following eligibility criteria were applied: (1) squamous cell carcinoma of the esophagus or gastroesophageal junction identified by histopathological examination; (2) treatment with esophagectomy plus lymphadenectomy with curative intent; and (3) complete pathologic reports and follow-up data. Patients who underwent non-curative (R1) resection and patients who died in hospital were excluded. Patients who received (neo)adjuvant therapy were also included in this analysis. All patients were restaged using the 7(th) edition of the Union for International Cancer Control and the American Joint Committee on Cancer TNM staging systems. Univariate and multivariate analyses were performed to identify the prognostic factors for survival. Survival curves were plotted using the Kaplan-Meier method, and the log-rank test was used to evaluate differences between the subgroups. RESULTS Of the 1033 patients, 273 patients received (neo)adjuvant therapy, and 760 patients were treated with surgery alone. The median follow-up time was 51.6 mo (range: 5-112 mo) and the overall 5-year survival rate was 36.4%. Gender, "pT" and "pN" descriptors, (neo)adjuvant therapy, and the 7(th) edition TNM stage grouping were independent prognostic factors in the univariate and multivariate analyses. However, neither histologic grade nor cancer location were independent prognostic factors in the univariate and multivariate analyses. The 5-year stage-based survival rates were as follows: IA, 84.9%; IB, 70.9%; IIA, 56.2%; IIB, 43.3%; IIIA, 37.9%; IIIB, 23.3%; IIIC,12.9% and IV, 3.4%. There were significant differences between each adjacent staging classification. Moreover, there were significant differences between each adjacent pN and pM subgroup. According to the pT descriptor, there were significant differences between each adjacent subgroup except between pT3 and pT4 (P = 0.405). However, there was no significant difference between each adjacent histologic grade subgroup and between each adjacent cancer location subgroup. CONCLUSION The 7(th) edition is considered to be valid for patients with resected ESCC. However, the histologic grade and cancer location were not prognostic factors for ESCC.

Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma

Validation of the Postneoadjuvant Therapy Pathological Stage of the American Joint Committee on Cancer (AJCC) 8th Edition for Predicting Outcomes of Esophageal Squamous Cell Carcinoma (ESCC) Patients Receiving Neoadjuvant Chemoradiotherapy (CRT) Followed by Esophagectomy.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

Evaluation of the 7thedition of the TNM Classification in Patients with Resected Esophageal Squamous Cell Carcinoma

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma

Validation of the 7th edition American Joint Committee on cancer staging system for esophageal squamous cell carcinoma.

Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study

Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems

Prognostic factors and outcome for patients with esophageal squamous cell carcinoma underwent surgical resection alone: evaluation of the seventh edition of the American Joint Committee on Cancer staging system for esophageal squamous cell carcinoma.

A New Clinical Staging System for Esophageal Cancer to Predict Survival after Definitive Chemoradiation or Radiotherapy

Comparison of the Prognostic Difference Between Yptnm and Equivalent Ptnm Stages in Esophageal Squamous Cell Carcinoma Based on the 8th Edition of AJCC Classification

448. THE PRIMARY TUMOR BURDEN SCORE: A NOVEL CLINICOPATHOLOGICAL STAGING TOOL FOR PATIENTS WITH ESOPHAGEAL CARCINOMA RECEIVING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY

Analysis of New N Descriptors on Prognosis of Esophageal Cancer with Positive Lymph Nodes in a Chinese Population.

Worldwide Esophageal Cancer Collaboration: Neoadjuvant Pathologic Staging Data.

Is the new distribution of early esophageal adenocarcinoma stages improving the prognostic prediction of the 8 edition of the TNM staging system for esophageal cancer?

Comparison between AJCC 8th edition gastric and esophageal ypTNM classification system in Siewert II esophagogastric junction adenocarcinomas: A retrospective study based on Eastern and Western Data

[Comparison of the Superiority of Different TNM Staging Systems in Siewert III Adenocarcinoma of Esophagogastric Junction].

Application of the Proposed Eighth Edition of the American Joint Committee on Cancer/Union of International Cancer Control Esophageal Cancer Staging System in Esophageal Cancer Patients

Evaluation of the 7th Edition of the TNM Classification for Lung Cancer at a Single Institution.

[Prognostic Analysis of Cervical Lymph Node Metastasis in Patients with Thoracic Esophageal Squamous Cell Carcinoma].

Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypTO) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery